



Attorney Docket No.: 6213.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Thomas-Hoeg-Jensen et al. Confirmation No: 1019

Application No.: 09/870,884

Group Art Unit: 1654

Filed: May 31, 2001

Examiner: Russel, Jeffrey E.

For: Glucose Dependent Release Of Insulin From Glucose Sensing Insulin Derivatives

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than the one listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. Journal of Organic Chemistry, Eggert et al., (1999) Vol. 64, pages 3846-3852.

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

02/06/2006 SFELEKE1 00000018 141447 09870884

02 FC:1806 180.00 DA

Attorney Docket No.: 6213.200-US  
Application No.: 09/870,884  
Filed: May 31, 2001  
Inventors: Thomas Hoeg-Jensen et al.


This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Please charge any additional fees, should they be required, to Novo Nordisk® Pharmaceuticals, Inc. Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 2, 2006



Rosemarie R. Wilk-Orescan, Reg. No. 45,220  
Novo Nordisk Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

CUSTOMER NUMBER  
23650  
PATENT TRADEMARK OFFICE

FORM PTO-1449  
(Rev. 5-92)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6213.200-US

Serial No. 09/870,884

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant **Thomas-Hoeg-Jensen et al.**

(Use several sheets if necessary)

Filing Date **May 31, 2001**Group **1654**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1	Journal of Organic Chemistry, Eggert et al., (1999) Vol. 64, pages 3846-3852.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.